Loading cancer entity…
Loading cancer entity…
Clinical trials
101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05609942 | Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies(AZURE) | terminated | Phase 1 | 9 | Blueprint Medicines CorporationINDUSTRY | 7 | Apr 10, 2025 | clinicaltrials |
| NCT03214666 | GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies | terminated | Phase 1 / Phase 2 | 12 | GT Biopharma, Inc.INDUSTRY | 1 | Nov 10, 2022 |
| clinicaltrials |
Data updated 22 days agoSource updated Apr 10, 2025source: clinicaltrials